No Data
No Data
[IPO Monthly Report] The Hong Kong IPO market saw a surge in subscription popularity and a significant decrease in the rate of IPOs breaking below the issue price in June. The expectations of the "Big Four" were mixed with both sorrow and joy.
In the first half of 2024, Hong Kong's IPO market continued its recent sluggish trend due to external market factors, global economic uncertainty, and cautious investor sentiment. The "Big Four" lowered their forecast for Hong Kong's annual IPO fundraising at the beginning of the year, but PwC expects Hong Kong's new IPO fundraising to exceed HKD 100 billion this year. PwC stated that the reduction in bearish factors, high demand for funding for business development, and the end of the interest rate hike cycle will bring back funds from Europe, America, and the Middle East to Asia, which is beneficial for market liquidity and valuation improvement. After six months of market baptism, PwC finally gave in and lowered Hong Kong's...
Hong Kong stock market changes | Yimai Yangguang (02522) fell more than 8%, the stock price temporarily showed five consecutive declines. The company is a leading enterprise in the domestic medical imaging field.
Yimaiyangguang (02522) fell more than 8%, as of press time, it fell 8.13%, reporting HKD 16.5, with a turnover of HKD 1.4343 million.
Hong Kong stock anomaly | Yimaiyangguang (02522) plunged more than 20% in early trading and fell below the issue price. The company is a leading enterprise in the field of medical imaging in China.
In early trading, Yimai Yangguang (02522) plummeted by more than 20%, hitting a low of HK$14.5, once again falling below the issue price of HK$14.98. As of press time, it has fallen 18.18% to HK$15.12, with a turnover of HK$3.6319 million.
HK stocks news | Yimaiyangguang (02522) rose more than 19%, hitting a new high, with a cumulative increase of more than 50% compared to the IPO price. The company's profit-making ability has been improving year by year.
According to the Wisdom Finance App, Yimaiyangguang (02522) rose over 19% to a record high of 23.2 Hong Kong dollars, an increase of over 54% from the IPO price of 14.98 Hong Kong dollars. As of press time, it is up 18.37% to 22.75 Hong Kong dollars, with a turnover of 11.1282 million Hong Kong dollars. It is reported that Yimaiyangguang, as a leading enterprise in the field of domestic medical imaging, operates a total of 97 imaging centers throughout the country. The prospectus shows that in 2021, 2022, and 2023, Yimaiyangguang's revenue will be 592 million yuan, 784 million yuan, and 929 million yuan, respectively, with a compound annual growth rate of
Nanjing Gaoke's Equity Investment Project Rimag Group Lists on Hong Kong Bourse
Nanjing Gaoke (SHA:600064) on Friday said its equity investment project, Jiangxi Rimag Group (HKG:2522), will list on the Hong Kong Stock Exchange. Rimag Group's shares will be listed on the Hong Kong
Rimag Group Ekes Out Gain in Hong Kong Debut
Jiangxi Rimag Group (HKG:2522) managed to eke out a marginal gain on its market debut in Hong Kong on Friday morning. The Chinese medical imaging company opened at HK$15 per share, slightly up from th
No Data